open access

Vol 7, No 2 (2011)
REVIEW ARTICLES
Published online: 2011-06-22
Get Citation

Diagnosis and treatment of patients with endocrine pancreatic cancer, including cases of mixed adenoneuroendocrine origin

Alicja Hubalewska-Dydejczyk, Anna Sowa-Staszczak, Agnieszka Stefańska
Onkol. Prak. Klin 2011;7(2):49-57.

open access

Vol 7, No 2 (2011)
REVIEW ARTICLES
Published online: 2011-06-22

Abstract

Pancreatic neuroendocrine tumours (PNT) belong to the group of gastroenteropancreatic neuroendcorine tumours (GEP-NET). Pancreatic neuroendocrine tumours are relatively rare tumours, but recently their incidence has been increasing. Except the mixed adenoneuroendocrine carcinoma, where the exocrine part is the prognostic factor and also determines the treatment method, PNT have usually better prognosis than adenocarcinoma of the pancreas. But prognosis depends mainly on the stage of the disease at the time of diagnosis. Therefore the diagnostic methods — histopathological, immunohistochemical, biochemical and imaging (both anatomical and metabolic) are still improving. The proper diagnosis and staging of the disease determine further decisions on therapeutic options. We can observe also the improvement of treatment methods used in case of PNT. This is visible in the field of use of characteristic klasyfeatures of neuroendocrine cells such as somatostatin receptors’ expression. Promising are also the results of clinical trials with new agents — inhibitors of angiogenesis and proliferation of the tumour cells (targeted therapy) and new schemes of systemic chemotherapy. This development is particularly important in the cases where the diagnosis is made at the advanced stages of the disease and due to inoperable primary tumour and/or dissemination of the process surgical treatment is not possible or the effect of this treatment is worse than expected.
Onkol. Prak. Klin. 2011; 7, 2: 49–57

Abstract

Pancreatic neuroendocrine tumours (PNT) belong to the group of gastroenteropancreatic neuroendcorine tumours (GEP-NET). Pancreatic neuroendocrine tumours are relatively rare tumours, but recently their incidence has been increasing. Except the mixed adenoneuroendocrine carcinoma, where the exocrine part is the prognostic factor and also determines the treatment method, PNT have usually better prognosis than adenocarcinoma of the pancreas. But prognosis depends mainly on the stage of the disease at the time of diagnosis. Therefore the diagnostic methods — histopathological, immunohistochemical, biochemical and imaging (both anatomical and metabolic) are still improving. The proper diagnosis and staging of the disease determine further decisions on therapeutic options. We can observe also the improvement of treatment methods used in case of PNT. This is visible in the field of use of characteristic klasyfeatures of neuroendocrine cells such as somatostatin receptors’ expression. Promising are also the results of clinical trials with new agents — inhibitors of angiogenesis and proliferation of the tumour cells (targeted therapy) and new schemes of systemic chemotherapy. This development is particularly important in the cases where the diagnosis is made at the advanced stages of the disease and due to inoperable primary tumour and/or dissemination of the process surgical treatment is not possible or the effect of this treatment is worse than expected.
Onkol. Prak. Klin. 2011; 7, 2: 49–57
Get Citation

Keywords

pancreatic neuroendocrine tumours; somatostatin analogues; peptide receptor radionuclide therapy; targeted therapy

About this article
Title

Diagnosis and treatment of patients with endocrine pancreatic cancer, including cases of mixed adenoneuroendocrine origin

Journal

Oncology in Clinical Practice

Issue

Vol 7, No 2 (2011)

Pages

49-57

Published online

2011-06-22

Bibliographic record

Onkol. Prak. Klin 2011;7(2):49-57.

Keywords

pancreatic neuroendocrine tumours
somatostatin analogues
peptide receptor radionuclide therapy
targeted therapy

Authors

Alicja Hubalewska-Dydejczyk
Anna Sowa-Staszczak
Agnieszka Stefańska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl